Autolus Therapeutics (NASDAQ:AUTL): Q3 GAAP EPS of -$0.61 beats by $0.25.
Revenue of $0.3M (-3.2% Y/Y) misses by $0.3M.
Cash and equivalents of $229.4M.
Thursday, November 7, 2019
AVROBIO EPS beats by $0.02
AVROBIO (NASDAQ:AVRO): Q3 GAAP EPS of -$0.57 beats by $0.02.
Cash and cash equivalents of $206.36M.
Ra Pharmaceuticals EPS misses by $0.05, beats on revenue
Ra Pharmaceuticals (NASDAQ:RARX): Q3 GAAP EPS of -$0.55 misses by $0.05.
Revenue of $3M beats by $2.62M.
Corbus Pharmaceuticals EPS beats by $0.05, beats on revenue
Corbus Pharmaceuticals (NASDAQ:CRBP): Q3 GAAP EPS of -$0.32 beats by $0.05.
Revenue of $2.59M (+137.6% Y/Y) beats by $0.75M.
Shares +4% PM.
Atara Biotherapeutics EPS beats by $0.10
Atara Biotherapeutics (NASDAQ:ATRA): Q3 GAAP EPS of -$1.31 beats by $0.10.
Cash and cash equivalents of $94.43M
Meridian Bioscience EPS beats by $0.04, beats on revenue
Meridian Bioscience (NASDAQ:VIVO): Q3 Non-GAAP EPS of $0.13 beats by $0.04; GAAP EPS of $0.10 beats by $0.02.
Revenue of $50.8M (-4.3% Y/Y) beats by $0.23M.
Shares -3% PM.
Rocket Pharmaceuticals EPS beats by $0.13
Rocket Pharmaceuticals (NASDAQ:RCKT): Q3 GAAP EPS of -$0.38 beats by $0.13.
Cash, cash equivalents and investments of $240.56M.
Subscribe to:
Comments (Atom)